MilliporeSigma Calbiochem ATR Inhibitor IV
A cell-permeable phenylpyrazine derivative that acts as a potent, ATP-competitive ( K i = 13nM; IC50 /[ATP] = 70 nM/50µM and 128 nM/100µM), ATR-selective inhibitor with much reduced or little potency against 4 related PIKKs ( K Manufacturer: MilliporeSigma 5.04972.0001
Manufacturer: MilliporeSigma 5.04972.0001
DescriptionA cell-permeable phenylpyrazine derivative that acts as a potent, ATP-competitive ( K i= 13nM; IC50/[ATP] = 70 nM/50µM and 128 nM/100µM), ATR-selective inhibitor with much reduced or little potency against 4 related PIKKs ( K i= 2.2, 3.9, 16, and >1µM, respectively, against DNA-PK, PI 3-Kγ, ATM, and mTOR) and 50 other kinases. Shown to selectively inhibit ATR-dependent H2AX Ser139 and Chk1 Ser345 phosphorylation (complete inhibition at 10µM in HT29 and HFL1 cultures) without affecting ATM- and DNA-PK-mediated H2AX or ATM-mediated Chk2 phosphorylation. Short-term (24 h) VE-821 treatment, either alone or in synergy with Cisplatin (Cat. No. 232120), results in reversible cytostatic growth arrest regardless of cellular ATM-p53 pathway activity, while cytotoxicity and Cisplatin synergism in cell death induction is reported to occur only upon long-term VE-821 exposure (≥72 h) in cultures with ATM-p53 pathway defects.
Please note that the molecular weight for this compound is batch-specific due to variable water content.
|98% by HPLC|
|Protect from Light|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok